Table 2 Clinical outcomes of patients with middle to lower third rectal adenocarcinoma receiving neoadjuvant concurrent chemoradiotherapy followed by trans-anal total mesorectal excision assisted by single port laparoscopic surgery
| Â | n (%) |
|---|---|
Pathologic T stages | |
 ypT0 | 5 (21.74) |
 ypT1 | 5 (21.74) |
 ypT2 | 9 (39.13) |
 ypT3 | 4 (17.39) |
Pathologic N stages | |
 ypN0 | 19 (82.61) |
 ypN1 | 4 (17.39) |
Pathologic response | |
 Complete response | 5 (21.74) |
 Partial response | 18 (78.26) |
 No response | 0 (0.00) |
Distal margin status | |
 R0 | 23 (100.00) |
 R1 | 0 (0.00) |
 R2 | 0 (0.00) |
Circumferential resection margin status | |
 R0 | 21 (91.30) |
 R1 | 2 (8.70) |
 R2 | 0 (0.00) |
Lymph nodes harvested, mean (range) | 15.3 (6-42) |
Operative time (min), mean (range) | 366 (240-480) |
Estimated blood loss (mL), mean (range) | 159 (10-650) |
Conversion | 1 (4.35) |
30-days complication | 5 (21.74) |
Mobilization of splenic flexure | 19 (82.61) |
Inter-sphincter resection | 14 (60.87) |
Type of anastomosis (hand-sewn) | 14 (60.87) |
Type of anastomosis (stapled) | 9 (39.13) |
Length of hospital stays (days), mean (range) | 8.4 (6-22) |